WSO - January 2024 - 66

66
International Journal of Stroke 19(1)
article: TD reports consultancy for Medtronic. JMO reports consultancy
for Bioxodes, Abbvie, and Acticor, and speaker fees from
Boehringer Ingelheim and Bristol Myers Squibb. JG reports a
Swiss National Funds grant for MRI in stroke. UF reports research
grants from Medtronic BEYOND SWIFT registry, the Swiss
National Science Foundation, and the Swiss Heart Foundation;
consulting fees from Medtronic, Stryker, and CSL Behring (fees
paid to institution); has membership of a data safety monitoring
board for the IN EXTREMIS trial and the TITAN trial; and was
on the advisory board for Portola (Alexion; fees paid to institution).
JK reports financial support from Medtronic for the
BEYOND SWIFT registry (fees paid to institution); and research
grants from the Swiss National Science Foundation supporting the
TECNO trial (fees paid to institution), Swiss Academy of Medical
Sciences supporting MRI research (fees paid to institution), and
Swiss Heart Foundation supporting cardiac MRI in the aetiological
work-up of stroke patients (fees paid to institution).
Funding
The author(s) received no financial support for the research,
authorship, and/or publication of this article.
ORCID iDs
Adnan Mujanovic
Felix Ng
Jean Marc Olivot
Thanh N Nguyen
https://orcid.org/0000-0002-6839-7134
https://orcid.org/0000-0001-6973-8677
https://orcid.org/0000-0003-2027-2276
https://orcid.org/0000-0002-2810-1685
Supplemental material
Supplemental material for this article is available online.
References
1. Seker F, Qureshi MM, Möhlenbruch MA, et al. Reperfusion
without functional independence in late presentation of stroke
with large vessel occlusion. Stroke 2022; 53: 3594-3604.
2. Fischer U, Kaesmacher J, Strbian D, et al. Thrombectomy
alone versus intravenous alteplase plus thrombectomy in
patients with stroke: an open-label, blinded-outcome, randomised
non-inferiority trial. Lancet 2022; 400: 104-115.
3. Tanaka K, Goyal M, Menon BK, et al. Significance of baseline
ischemic core volume on stroke outcome after endovascular
therapy in patients age ⩾75 years: a pooled analysis of individual
patient data from 7 trials. Stroke 2022; 53: 3564-3571.
4. Van Kranendonk KR, Treurniet KM, Boers AMM, et al.
Hemorrhagic transformation is associated with poor functional
outcome in patients with acute ischemic stroke due to a
large vessel occlusion. J Neurointerv Surg 2019; 11: 464-468.
5. Del Zoppo GJ and Mabuchi T. Cerebral microvessel responses to
focal ischemia. J Cereb Blood Flow Metab 2003; 23: 879-894.
6. Dalkara T and Arsava EM. Can restoring incomplete microcirculatory
reperfusion improve stroke outcome after thrombolysis.
J Cereb Blood Flow Metab 2012; 32: 2091-2099.
7. Burrows FE, Bray N, Denes A, Allan SM and Schiessl I.
Delayed reperfusion deficits after experimental stroke account
for increased pathophysiology. J Cereb Blood Flow Metab
2015; 35: 277-284.
8. Little JR and Sundt TM. Microcirculatory obstruction in focal
cerebral ischemia: an electron microscopic investigation in
monkeys. Stroke 1976; 7: 25-30.
International Journal of Stroke, 19(1)
9. Ames A 3rd, Wright RL, Kowada M, Thurston JM and Majno G.
Cerebral ischemia. II. The no-reflow phenomenon. Am J
Pathol 1968; 52: 437-453.
10. El Amki M, Glück C, Binder N, et al. Neutrophils obstructing
brain capillaries are a major cause of no-reflow in ischemic
stroke. Cell Rep 2020; 33: 1-9.
11. Rubiera M, Garcia-Tornel A, Olivé-Gadea M, et al. Computed
tomography perfusion after thrombectomy: an immediate surrogate
marker of outcome after recanalization in acute stroke.
Stroke 2020; 51: 1736-1742.
12. Marks MP, Lansberg MG, Mlynash M, et al. Angiographic
outcome of endovascular stroke therapy correlated with MR
findings, infarct growth, and clinical outcome in the DEFUSE
2 trial. Int J Stroke 2014; 9: 860-865.
13. Ng FC, Churilov L, Yassi N, et al. Prevalence and significance
of impaired microvascular tissue reperfusion despite macrovascular
angiographic reperfusion (no-reflow). Neurology
2022; 98: e790-e801.
14. Renu A, Millan M, San Roman L, et al. Effect of intra-arterial
alteplase vs placebo following successful thrombectomy on
functional outcomes in patients with large vessel occlusion
acute ischemic stroke: the CHOICE randomized clinical trial.
J Am Med Assoc 2022; 327: 826-835.
15. McCartney PJ, Maznyczka AM, Eteiba H, et al. Low-dose
alteplase during primary percutaneous coronary intervention
according to ischemic time. J Am Coll Cardiol 2020; 75:
1406-1421.
16. Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on
angiographic revascularization grading standards for acute
ischemic stroke: a consensus statement. Stroke 2013; 44:
2650-2663.
17. Meier P and Zierler K. On the theory of the indicator-dilution
method for measurement of blood flow and volume. J Appl
Physiol 1954; 6: 731-744.
18. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool
for assessing risk of bias in non-randomised studies of interventions.
BMJ 2016; 355: 1-7.
19. McGuinness LA and Higgins JPT. Risk-Of-Bias VISualization
(robvis): an R package and Shiny web app for visualizing riskof-bias
assessments. Res Synth Methods 2021; 12: 55-61.
20. De Silva DA, Fink JN, Christensen S, et al. Assessing reperfusion
and recanalization as markers of clinical outcomes
after intravenous thrombolysis in the echoplanar imaging
thrombolytic evaluation trial (EPITHET). Stroke 2009; 40:
2872-2874.
21. Ng FC, Coulton B, Chambers B and Thijs V. Persistently
elevated microvascular resistance postrecanalization a clinical
marker of no-reflow phenomenon. Stroke 2018; 49:
2512-2515.
22. Zhao W, Liu R, Yu W, et al. Elevated pulsatility index is
associated with poor functional outcome in stroke patients
treated with thrombectomy: a retrospective cohort study. CNS
Neurosci Ther 2022; 28: 1568-1575.
23. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance
imaging profiles predict clinical response to early reperfusion:
the diffusion and perfusion imaging evaluation for
understanding stroke evolution (DEFUSE) study. Ann Neurol
2006; 60: 508-517.
24. Bai X, Yu F, Tian Q, et al. Clinical significance and influencing
factors of microvascular tissue reperfusion after
https://www.orcid.org/0000-0002-6839-7134 https://www.orcid.org/0000-0001-6973-8677 https://www.orcid.org/0000-0003-2027-2276 https://www.orcid.org/0000-0002-2810-1685
WSO - January 2024

Table of Contents for the Digital Edition of WSO - January 2024
